2024-05-16
Beimei Pharma and Sol-Gel Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Shenzhen Beimei Pharmaceutical Co., Ltd. ("Beimei Pharma") announced that on May 15th, 2024, an asset purchase agreement (the "Agreement") was signed with Sol-Gel Technologies, Ltd. ("Sol-Gel", Nasdaq stock Code: SLGL) to acquire all relevant assets of dermatology product TWYNEO® in the mainland of China, Hong Kong, Macau, Taiwan and I...
More +